Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

View:
Post by CandyC on Mar 23, 2021 12:44am

New to Antibe

Hi all,
I am new to this stock. I seen it on BNN Market Call a month ago. Could someone give me a condensed overview and outlook? Thanks in advance. Candy
Comment by MikeStock on Mar 23, 2021 7:34am
Look up the user MrMugsy and read a few of his posts. That will provide a fairly concise update. Hope this helps. 
Comment by Marky1 on Mar 23, 2021 7:46am
Mike..you gave him great advice, but this person that you sent this advice to, is doing the same thing on many many other sights. Click on his name and see what I mean Merci JM
Comment by MikeStock on Mar 23, 2021 9:06am
Guess you can't trust anyone anymore. It's a shame. 
Comment by CandyC on Mar 23, 2021 9:47am
Correct. I am new to these 5 companies and simply like a condensed overview as they are all penny stocks that I seen on Market Call. There isn't much information as large caps. Sorry if it rubs people the wrong way 
Comment by 123ABC on Mar 23, 2021 10:13am
  Ton of info out there, is it too much to Google Antibe Therapeutics?
Comment by Scrivs187 on Mar 23, 2021 10:23am
This is a chat forum to discuss Antibe...is it too much to not be such an asshat?
Comment by TriumphSpitSix on Mar 24, 2021 12:16am
Correct. It's "a chat forum to discuss Antibe" and one can only "discuss" a topic after he or she has gotten off his or her lazy @ss and done some small amount of research on their own, not come here with the expectation to have others spoon-feed their due diligence and research to them. You think it's being "an asshat" to expect a modicum of effort from ...more  
Comment by 123ABC on Mar 24, 2021 3:19am
Beautiful response, couldn't have said it better myself.
Comment by Scrivs187 on Mar 24, 2021 8:56am
Indeed, i do think he's an asshat for a condescending comment suggesting to use google to a new comer.  Although, the tone was slightly better than the diarrhea and regular rhetoric of bashing the stock and management he spews.. but to each their own. I dont expect anything from anyone on these forums but when someone asks for info/help just do it.
Comment by WalkOverTheStrt on Mar 23, 2021 9:41am
Learn to fish https://antibethera.com/wp-content/uploads/2021/03/Antibe-Corporate-Presentation-March-2021.pdf
Comment by Scrivs187 on Mar 23, 2021 10:26am
Good stuff on their website and best to filter back a bit through SH to see some of the quality posts some of the Antibe members have posted. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities